SeroELISA Chlamydia IgA Assay
The SeroELISA Chlamydia IgA Assay is For Research Use Only
Size: 1×96 wells
Sensitivity: Cutt-Off Control
Incubation Time: 2 hours
Sample Type: Serum
Sample Size: 10 µL
Human serum to be tested is brought into contact with the antigenic material coating the microtiter wells. Specific antibody, if present in the patient serum will bind to the attached antigen, a complex is formed and all the serum components are washed away in the wash phase. Horseradish peroxidase (HRP) conjugated anti-human IgA (alpha-chain specific) is added to the wells. If an antigen-antibody complex was formed in the previous step, the peroxidase conjugated antibody will bind to the antibody moiety of the complex. If no antigen-antibody complex was formed in the previous step, the conjugate is washed away in the wash phase. TMB-Substrate is added. A positive reaction is indicated by a blue to deep blue color which develops in the test wells following enzymatic reaction of the peroxidase moiety with peroxide and the chromogen reactant. After the enzymatic reaction is stopped by an acidic solution, the absorbance of the test wells is determined at 450nm by a spectrophotometer. The absorbance at 450nm is indicative of IgA anti-Chlamydia titer in patient serum specimens.
Hospitalized patients, infected with Neisseria gonorrhea, Staphylococcus aureus and Peptostreptococcus anaerobius, who were diagnosed by commercial serology kits, were also tested with the SeroELISA Chlamydia kit. There was no significant cross-reaction detected.
SeroELISA Chlamydia True IgM Assay
SeroELISA Chlamydia IgG Assay
SeroCP Quant C. pneumoniae IgA ELISA Assay Kit
Chlamydia is a gram-negative obligate intracellular bacteria that causes acute and chronic diseases in mammalian and avian species. The genus Chlamydia is comprised of four species: C.trachomatis, C.pneumoniae, C.psittaci and C. pecorum. C.trachomatis is divided into 15 serovars (1). Serovars A, B, Ba and C are agents of trachoma (2), the leading cause of preventable blindness endemic in third world countries. Serovars L1-L3 are the agents of lymphogranuloma venereum. Serovars D-K are the common cause of sexually transmitted genital infection worldwide: cervicitis, endometritis/ salpingitis (3) in females and urethritis (4) in both males and females. Endometritis/salpingitis can lead to tubal occlusion with a higher risk of extra uterine pregnancy and infertility. Genital infection may cause an acute and persistent infection occasionally without any clinical symptoms. Generally, these infections are treatable once they are diagnosed. However without any treatment the infection may progress to a severe chronic inflammation leading to infertility, ectopic pregnancy, induced abortion or premature delivery. Moreover, infants to infected mothers may be infected during birth, leading to conjunctivitis or pneumonia (5). C.pneumoniae is an important respiratory pathogen in humans and causes up to 10% of community-acquired pneumonia cases. It has been associated with acute respiratory diseases, pneumonia, asthma, bronchitis, pharyngitis, acute chest syndrome of sickle cell disease, coronary heart disease, and Guillain-Barre syndrome (6). C.psittaci infects a diverse range of host species from mollusks to birds to mammals and also causes severe pneumonia. Serodiagnostic tests, which rely on specific immunologic markers, serve as a non-invasive diagnostic tool in identification of both distal and deep infections (7). Chlamydia, specific IgA antibody appears to be a reliable immunological marker of primary, chronic and recurrent infections (8). Anti-Chlamydia IgA antibody is of diagnostic value in non-gonococcal urethritis (NGU) patients (9), in women with acute salpingitis and in women with mechanical infertility (10) in ectopic pregnancy, prostatitis, epididymitis, conjunctivitis, Reiter’s syndrome (10) and pneumonitis. The SeroELISA Chlamydia test employs the L2 serovar broadly reacting antigen of C. trachomatis. It will detect C. trachomatis, C. psittaci and C. pneumoniae (TWAR) antibodies.